Washington University School of Medicine

Digital Commons@Becker
Open Access Publications
2010

Immunotherapy for sepsis - A new approach against an ancient
foe
Richard S. Hotchkiss
Washington University School of Medicine in St. Louis

Steven Opal
Alpert Medical School of Brown University

Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs

Recommended Citation
Hotchkiss, Richard S. and Opal, Steven, ,"Immunotherapy for sepsis - A new approach against an ancient
foe." The New England Journal of Medicine. 363,1. 87-9. (2010).
https://digitalcommons.wustl.edu/open_access_pubs/3557

This Open Access Publication is brought to you for free and open access by Digital Commons@Becker. It has been
accepted for inclusion in Open Access Publications by an authorized administrator of Digital Commons@Becker.
For more information, please contact vanam@wustl.edu.

The

n e w e ng l a n d j o u r na l

of

m e dic i n e

clinical implications of basic research

Immunotherapy for Sepsis — A New Approach
against an Ancient Foe
Richard S. Hotchkiss, M.D., and Steven Opal, M.D.
Septic shock is traditionally viewed as an excessive systemic inflammatory reaction to invasive
microbial pathogens, yet efforts to improve the
outcome of patients with sepsis by means of inhibitors of proinflammatory cytokines and mediators have been unsuccessful. Occasionally, patients
present with an exaggerated systemic inflammatory response to highly virulent pathogens (such
as in cases of meningococcemia) and rapidly
succumb. However, the vast majority of patients
with sepsis survive the initial insult, only to end
up in the intensive care unit with sepsis-induced
multiorgan dysfunction days or weeks later. Sepsisinduced immunosuppression is increasingly recognized as the overriding immune dysfunction
in these vulnerable patients.1
The clinical relevance of this immunosuppressed state is evidenced by the frequent occurrence of infection with relatively avirulent and
often multidrug-resistant bacterial, viral, or fungal
pathogens such as species of stenotrophomonas,
acinetobacter, candida, pseudomonas, enterococcus, and cytomegalovirus. In light of progressive
antimicrobial resistance and the paucity of new
antimicrobial agents entering the developmental
pipeline, the care of patients with sepsis is increasingly challenging.2 Sepsis can be considered
to represent a race between the pathogens and
the host immune response; pathogens seek an
advantage by incapacitating various aspects of
host defenses. For example, they induce the apoptotic depletion of immune effector cells, suppress
the expression of major-histocompatibility-complex class II molecules, increase expression of
negative costimulatory molecules, increase antiinflammatory cytokines, and augment levels of
regulatory T cells and myeloid-derived suppressor cells (Fig. 1). The prevention of sepsis-induced
immunosuppression, or its treatment if it occurs,
is a research priority.
A recent study by Said and colleagues3 pro-
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vides insights into the molecular mechanisms
that underlie immune depression following sustained inflammation, such as occurs in patients
with either chronic viral infections or protracted sepsis. These investigators studied a critical
monocyte–macrophage protein known as programmed death 1 (PD-1), which is found in patients infected with the human immunodeficiency virus (HIV). PD-1, a negative costimulatory
molecule expressed on immune effector cells, is
up-regulated along with its cognate ligand PD-L1
(also expressed on effector cells) during chronic
HIV infection. Said and colleagues found that
microbial mediators translocate across the intestinal epithelium in chronic HIV-induced inflammation and are recognized by toll-like receptors.
Persistent activation of the innate immune system by these intestinally derived microbial products up-regulates the expression of PD-1 and
PD-L1 on various immune cells.
PD-1 impairs immunity by inducing apoptosis, increasing production of interleukin-10 (a key
antiinflammatory cytokine increased in sepsis),
preventing T-cell proliferation, and causing T cells
to become nonresponsive (“exhausted”). Said and
colleagues described a new mechanism by which
the interaction between PD-1 and PD-L1 induces
immunosuppression in patients with HIV. They
found that PD-1 activation results in the increased
production of interleukin-10 by monocytes from
persons infected with HIV. Moreover, the PD-1–
induced inhibition of CD4 T cells was itself inhibited by the blocking of the interleukin-10 receptor. Thus, PD-1 affects immunosuppression
through its effect on interleukin-10 expression.
These results suggest that blocking PD-1 may
improve the prognosis of patients with any of a
variety of chronic infections. These findings are
consistent with the improved survival in mice
with fungal infections, and in mice with bacterial sepsis, in which PD-1 was inhibited.4
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Figure 1. Reversal of Immunosuppression in Sepsis.
In many cases of sepsis, the immune system fails to eradicate the infectious pathogens, and a prolonged phase of sepsis-induced immunosuppression begins, characterized by a failure to eradicate the primary infection and by development of secondary nosocomial infections. This immunosuppression is mediated by multiple mechanisms, including massive apoptosis-induced depletion of lymphocytes
and dendritic cells, decreased expression of the cell-surface antigen–presenting complex HLA-DR, and increased expression of the negative costimulatory molecules programmed death 1 (PD-1), cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4), and B- and T-lymphocyte attenuator (BTLA) and their corresponding ligands (e.g., PD-1 ligand [PD-L1]). Furthermore, the numbers of regulatory T cells and
myeloid-derived suppressor cells (MDSCs) are increased, and there is a shift from a phenotype of inflammatory type 1 helper T (Th1)
cells to an antiinflammatory phenotype of type 2 helper T (Th2) cells characterized by the production of interleukin-10. The net result is
a severely compromised innate and adaptive immune system with poorly functional “exhausted” CD8 and anergic CD4 T cells. Targets
of potential immunotherapeutic approaches (shown in red) include agents that block apoptosis, block negative costimulatory molecules,
decrease the level of antiinflammatory cytokines, increase HLA-DR expression, and reactivate “exhausted” or anergic T cells. FLT-3L
denotes Fms-related tyrosine kinase 3 ligand, GM-CSF granulocyte–macrophage colony-stimulating factor, LFA-1 lymphocyte function–
associated antigen 1, and TNF-α tumor necrosis factor α.
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CLINICAL IMPLICATIONS OF BASIC RESEARCH

Although it is possible that immunostimulatory therapy exacerbates the hyperinflammatory
phase of sepsis or induces autoimmunity, clinical
trials of interferon-γ, a potent immunostimulatory agent, and granulocyte colony-stimulating
factor and granulocyte–macrophage colony-stimulating factor (GM-CSF) in patients with various
systemic inflammatory states did not elicit unbridled inflammatory reactions. Most patients
with refractory sepsis are so severely immunosuppressed that the development of hyperinflammation or autoimmunity is unlikely.
To prevent the extensive apoptosis-induced
depletion of immune effector cells in patients
with sepsis, one potential strategy is use of the
antiapoptotic, immunostimulatory cytokines interleukin-7 and interleukin-15; both agents have
shown efficacy in models of infection, including
sepsis. These cytokines, in preventing cell death,
diminish the immunosuppressive effect on phagocytic cells (which are relieved from disposing
of increased numbers of apoptotic cells). Interleukin-7 also restores the effector function of
lymphocytes and improves lymphocyte migration
by increasing the activity of integrins. Interleukin-7 is currently in clinical trials to treat cancer
and infection with hepatitis C virus and HIV.
In the future, immunotherapy will probably
be tailored to the individual patient on the basis
of specific laboratory or clinical findings. For
example, a recent trial of GM-CSF to treat sepsis
tested the effect only on patients in whom monocyte HLA-DR expression was significantly depressed.5 Flow-cytometric studies quantitating
the level of expression of negative costimulatory
molecules (such as PD-1 and PD-L1) on leukocytes, or rapid whole-blood stimulation assays
of cytokine secretion, could be used to guide
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immunotherapeutic decisions. Patients with cytomegalovirus infection or reactivation of herpes
simplex virus type 1 and those with sepsis due
to infection with opportunistic pathogens (such
as stenotrophomonas or acinetobacter) are good
candidates for immunoenhancing therapy.
An old saying goes, “Desperate diseases are
cured by desperate means or not at all.” Trials
of immunostimulatory agents should be undertaken, with close monitoring of innate and
adaptive immune function, in patients with demonstrable immunosuppression. Many potentially beneficial immunomodulatory agents (Fig. 1)
are currently in clinical trials for other indications and have reasonable safety profiles. We
speculate that such approaches will have wideranging effects and could represent a major advance in the field of infectious disease.
Disclosure forms provided by the authors are available with
the full text of this article at NEJM.org.
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